Loading...
XSTO
CEVI
Market cap341mUSD
Jul 10, Last price  
138.40SEK
1D
2.67%
1Q
-8.34%
Jan 2017
60.93%
IPO
989.76%
Name

CellaVision AB

Chart & Performance

D1W1MN
XSTO:CEVI chart
P/E
21.56
P/S
4.35
EPS
6.42
Div Yield, %
1.81%
Shrs. gr., 5y
Rev. gr., 5y
9.99%
Revenues
759m
+4.94%
74,565,000100,444,000108,974,000131,638,000155,402,000169,512,000179,851,000216,916,000239,390,000265,038,000309,312,000364,812,000461,772,000471,443,000565,552,000639,340,000677,292,000723,217,000758,968,000
Net income
153m
+8.78%
2,625,00025,054,00027,720,00038,349,00014,633,0006,451,00018,932,00031,465,00052,822,00059,800,00069,723,00088,688,00099,172,00089,480,000125,339,000118,335,000130,309,000140,722,000153,078,000
CFO
201m
+1.06%
6,666,0001,270,00020,580,00011,458,00032,015,00011,493,00027,272,00039,784,00087,997,00076,567,00087,898,00074,069,000125,993,00071,124,000159,717,000137,285,000196,436,000198,438,000200,532,000
Dividend
May 07, 20252.5 SEK/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

CellaVision AB (publ), a company established in Lund, Sweden, in 1994, specializes in the development and distribution of digital analytical solutions for blood and body fluid samples. Their offerings cater to the healthcare services sector, with a significant global presence spanning Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific region. The company's product portfolio includes advanced hardware such as the CellaVision DM1200 and CellaVision DM9600, which are designed to automatically capture digital images from blood smears and various body fluid preparations, alongside the CellaVision DC-1 analyzer. Complementing their instrumentation is a suite of specialized software applications. For instance, the CellaVision Peripheral Blood Application streamlines and standardizes the morphological examination of peripheral blood smears for laboratory professionals. Similarly, the CellaVision Advanced RBC Application facilitates a comprehensive evaluation of red blood cell morphology, while the CellaVision Body Fluid Application offers automated and standardized analysis for body fluid preparations. To enhance collaboration and flexibility, the CellaVision Remote Review Software eliminates geographical barriers in the smear review process. Further enriching their ecosystem are tools such as the CellaVision Server Software, which unifies workflows across single or multiple testing sites, and the CellaVision Dashboard, providing instant insights into analyzer and reviewer performance metrics. For staff development, the cloud-based CellaVision Proficiency Software aids laboratory managers in assessing and enhancing team competency in cell morphology. Educational resources include CellaVision CellAtlas, combining mini-lectures with an extensive cell image database. Finally, CellaVision VET extends their digital microscopy solutions to the field of veterinary hematology. Their clientele primarily consists of hospital and commercial diagnostic laboratories.
IPO date
May 28, 2007
Employees
235
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT